



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	94.53
Trade Time:	10:39 AM ET Feb 20, 2018
Change:	-0.73 (0.766%)
Day Range	94.22 - 95.40
52-Week Range	88.32 - 147.17
Volume	978,890

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®], ISTODAX[®] and IDHIFA[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 17, 2018
[OTEZLA® \(Apremilast\) Phase III Data Showed Significant Improvements in Patients with Active Behçet's Disease with Oral Ulcers](#)

Feb 15, 2018
[OTEZLA® \(Apremilast\) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis](#)

Feb 15, 2018
[Celgene Corporation Elects John Weiland to Its Board of Directors](#)

Feb 14, 2018
[Celgene Announces Additional \\$5 Billion Share Repurchase Authorization](#)

Feb 9, 2018
[Celgene Prices \\$4.5 Billion of Senior Unsecured Notes](#)

Upcoming Events [\[View all \]](#)

Feb 21, 2018 11:30 AM ET
[RBC Capital Markets 2018 Global Healthcare Conferenc](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

Feb 7, 2018
[Annual Report \(10-K\)](#)

Apr 27, 2017
[Proxy Statement \(DEF 14A\)](#)

Oct 26, 2017
[Quarterly Report \(10-Q\)](#)

Jul 27, 2017
[Quarterly Report \(10-Q\)](#)

Apr 27, 2017
[Quarterly Report \(10-Q\)](#)